Pre-analytical and analytical factors influencing Alzheimer's disease cerebrospinal fluid biomarker variability.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Clinica chimica acta; international journal of clinical chemistry

• Publication date

  2015-09-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.cca.2015.05.024PMID 26141614
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Importance and impact of preanalytical variables on Alzheimer disease biomarker concentrations in cerebrospinal fluid.

  2015cited by this paper
• Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.

  2014cited by this paper
• Additional Use of Aβ42/Aβ40 Ratio with Cerebrospinal Fluid Biomarkers P-Tau and Aβ42 Increases the Level of Evidence of Alzheimer's Disease Pathophysiological Process in Routine Practice

  2014cited by this paper
• The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative

  2014cited by this paper
• Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.

  2014cited by this paper
• Qualification of a Surrogate Matrix-Based Absolute Quantification Method for Amyloid-β42 in Human Cerebrospinal Fluid Using 2D UPLC-Tandem Mass Spectrometry

  2014cited by this paper
• Mass spectrometry-based candidate reference measurement procedure for quantification of amyloid-β in cerebrospinal fluid.

  2014cited by this paper
• Impact of harmonization of collection tubes on Alzheimer's disease diagnosis

  2014cited by this paper
• Amyloid-β 42/40 Cerebrospinal Fluid Concentration Ratio in the Diagnostics of Alzheimer's Disease: Validation of Two Novel Assays

  2014cited by this paper
• Quantification of tau in cerebrospinal fluid by immunoaffinity enrichment and tandem mass spectrometry.

  2014cited by this paper
• Amyloid-beta 42 adsorption following serial tube transfer

  2014cited by this paper
• Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: An update from the Alzheimer's Association Global Biomarkers Consortium

  2013cited by this paper
• Cerebrospinal Fluid Aβ1-40 Improves Differential Dementia Diagnosis in Patients with Intermediate P-tau181P Levels

  2013cited by this paper
• Pre-analytical factors influencing the stability of cerebrospinal fluid proteins.

  2013cited by this paper
• Identification of an important potential confound in CSF AD studies: aliquot volume

  2013influential reference
• CSF biomarker variability in the Alzheimer's Association quality control program

  2013cited by this paper
• Discriminatory and predictive capabilities of enzyme‐linked immunosorbent assay and multiplex platforms in a longitudinal Alzheimer's disease study

  2013cited by this paper
• Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update.

  2012cited by this paper
• Cerebrospinal fluid Aβ and tau level fluctuation in an older clinical cohort.

  2012cited by this paper
• Risk of Alzheimer's Disease Biological Misdiagnosis Linked to Cerebrospinal Collection Tubes

  2012cited by this paper
• Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative

  2012cited by this paper
• Study of the Adhesion of Neurodegenerative Proteins on Plasma-Modified and Coated Polypropylene Surfaces

  2012cited by this paper
• Hourly variability of cerebrospinal fluid biomarkers in Alzheimer's disease subjects and healthy older volunteers.

  2012cited by this paper
• The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

  2011cited by this paper
• Comparison of Immunosorbent Assays for the Quantification of Biomarkers for Alzheimer’s Disease in Human Cerebrospinal Fluid

  2011cited by this paper
• The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers

  2011cited by this paper
• The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

  2011cited by this paper
• Preanalytical Sample Handling and Sample Stability Testing for the Neurochemical Dementia Diagnostics

  2011cited by this paper
• Long-Term Stability of Alzheimer's Disease Biomarker Proteins in Cerebrospinal Fluid

  2011cited by this paper
• Comparison of post-dural puncture headache and low back pain between 23 and 25 gauge Quincke spinal needles in patients over 60 years: randomized, double-blind controlled trial.

  2011cited by this paper
• Nonspecific binding of Aβ42 to polypropylene tubes and the effect of Tween-20.

  2010cited by this paper
• Use of cerebrospinal fluid biomarkers in diagnosis of dementia across Europe

  2010influential reference
• Standardization of Assay Procedures for Analysis of the CSF Biomarkers Amyloid β (1-42), Tau, and Phosphorylated Tau in Alzheimer's Disease: Report of an International Workshop

  2010cited by this paper
• Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

  2010cited by this paper
• Confounding Factors Influencing Amyloid Beta Concentration in Cerebrospinal Fluid

  2010cited by this paper
• CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.

  2009cited by this paper
• The effect of preanalytical factors on stability of the proteome and selected metabolites in cerebrospinal fluid (CSF).

  2009cited by this paper
• A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease

  2009cited by this paper
• [Lumbar puncture].

  2008cited by this paper
• Fluctuations of csf amyloid-β levels : Implications for a diagnostic and therapeutic biomarker. Author's reply

  2007cited by this paper
• Influence of delayed CSF storage on concentrations of phospho-tau protein (181), total tau protein and beta-amyloid (1-42).

  2007cited by this paper
• Effect of sample collection tubes on cerebrospinal fluid concentrations of tau proteins and amyloid beta peptides.

  2006cited by this paper
• Standard vs atraumatic Whitacre needle for diagnostic lumbar puncture: A randomized trial

  2006cited by this paper
• International quality control survey of neurochemical dementia diagnostics.

  2006cited by this paper
• Alzheimer's disease

  2006cited by this paper
• Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology.

  2005cited by this paper
• The impact of blood contamination on the proteome of cerebrospinal fluid

  2005cited by this paper
• Effects of processing and storage conditions on amyloid beta (1-42) and tau concentrations in cerebrospinal fluid: implications for use in clinical practice.

  2005cited by this paper
• Cerebrospinal fluid amyloid β peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: Indication of carrier‐mediated epitope masking of amyloid β peptides

  2004cited by this paper
• Postlumbar Puncture Headache Syndrome

  2003cited by this paper
• Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid.

  2002cited by this paper
• Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values.

  2001cited by this paper
• Dynamics of brain-derived proteins in cerebrospinal fluid.

  2001cited by this paper
• Lumbar Puncture

  1958cited by this paper

• Evaluation of preanalytical factors on quantification of amyloid-β (1-42), phosphorylated tau 181, and total tau in cerebrospinal fluid

  2025cites this paper
• Promising clinical tools for specific Alzheimer disease diagnosis from plasma pTau217 and ApoE genotype in a cognitive disorder unit

  2025cites this paper
• Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease

  2025cites this paper
• Beyond Alzheimer's disease-translating biomarker insights across CNS diseases.

  2025cites this paper
• How well do plasma Alzheimer’s disease biomarkers reflect the CSF amyloid status?

  2024cites this paper
• BDNF Val66Met moderates episodic memory decline and tau biomarker increases in early sporadic Alzheimer’s disease

  2024cites this paper
• Alzheimer’s disease biomarkers in cerebrospinal fluid are stable with the Elecsys immunoassay to most pre-analytical influencing factors except freezing at -80 °C

  2023cites this paper
• Decreased cerebrospinal fluid Aβ 38, 40, 42, and 43 levels in sporadic and hereditary cerebral amyloid angiopathy.

  2023cites this paper
• Review and standard operating procedures for collection of biospecimens and analysis of biomarkers in new onset refractory status epilepticus

  2023cites this paper
• Agreement of cerebrospinal fluid biomarkers and amyloid-PET in a multicenter study

  2023cites this paper
• Tutorial review for peptide assays: An ounce of pre-analytics is worth a pound of cure.

  2023cites this paper
• Accuracy of plasma Aβ40, Aβ42, and p-tau181 to detect CSF Alzheimer’s pathological changes in cognitively unimpaired subjects using the Lumipulse automated platform

  2023cites this paper
• Different associations between amyloid-βeta 42, amyloid-βeta 40, and amyloid-βeta 42/40 with soluble phosphorylated-tau and disease burden in Alzheimer’s disease: a cerebrospinal fluid and fluorodeoxyglucose-positron emission tomography study

  2023cites this paper
• Maladies neurodégénératives et biomarqueurs du liquide céphalorachidien

  2023cites this paper
• Proteomic Discovery and Validation of Novel Fluid Biomarkers for Improved Patient Selection and Prediction of Clinical Outcomes in Alzheimer’s Disease Patient Cohorts

  2022cites this paper
• Establishment of combined diagnostic models of Alzheimer’s disease in a Chinese cohort: the Chongqing Ageing & Dementia Study (CADS)

  2022cites this paper
• Decision tree-based classification as a support to diagnosis in the Alzheimer’s disease continuum using cerebrospinal fluid biomarkers: insights from automated analysis

  2022cites this paper
• The Known Unknowns: An Overview of the State of Blood-Based Protein Biomarkers of Mild Traumatic Brain Injury

  2021cites this paper
• Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview

  2021cites this paper
• Marqueurs biologiques et maladie d’Alzheimer

  2021cites this paper
• Soluble APP-α and APP-β in cerebrospinal fluid as potential biomarkers for differential diagnosis of mild cognitive impairment

  2021cites this paper
• CCCDTD5: Clinical role of neuroimaging and liquid biomarkers in patients with cognitive impairment

  2021cites this paper
• Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases course—a joint PhD student course at University College London and University of Gothenburg

  2020cites this paper
• Pre‐analytical protocol for measuring Alzheimer's disease biomarkers in fresh CSF

  2020cites this paper
• Measurement of CSF core Alzheimer disease biomarkers for routine clinical diagnosis: do fresh vs frozen samples differ?

  2020cites this paper
• Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging

  2020cites this paper
• Potential of FTIR Spectroscopy Applied to Exosomes for Alzheimer’s Disease Discrimination: A Pilot Study

  2020cites this paper
• Current and Developing Methods for Diagnosing Alzheimer's Disease

  2019cites this paper
• Amyloid Beta Adsorption Problem with Transfer Plates in Amyloid Beta 1–42 IVD Kits

  2019cites this paper
• Validation of the Erlangen Score Algorithm for Differential Dementia Diagnosis in Autopsy-Confirmed Subjects

  2019cites this paper
• Key Pre‐analytical Considerations in LC‐MS Bioanalysis

  2019cites this paper
• Preanalytical sample handling recommendations for Alzheimer's disease plasma biomarkers

  2019cites this paper
• Considerations for Adapting Pre-existing Mechanistic Quantitative Systems Pharmacology Models for New Research Contexts

  2019cites this paper
• Differential diagnosis between Alzheimer's disease and other dementias: Role of cerebrospinal fluid biomarkers.

  2019cites this paper
• Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

  2019cites this paper
• Analytical and clinical performances of the automated Lumipulse cerebrospinal fluid Aβ42 and T-Tau assays for Alzheimer’s disease diagnosis

  2019cites this paper
• The standardization of cerebrospinal fluid markers and neuropathological diagnoses brings to light the frequent complexity of concomitant pathology in Alzheimer's disease: The next challenge for biochemical markers?

  2019cites this paper
• The CSF p-tau181/Aβ42 Ratio Offers a Good Accuracy "in Vivo" in the Differential Diagnosis of Alzheimer's Dementia.

  2019cites this paper
• Neue Biomarker für die Alzheimer-Krankheit in Liquor und Blut

  2019cites this paper
• Italian consensus recommendations for a biomarker‐based aetiological diagnosis in mild cognitive impairment patients

  2019cites this paper
• Reciprocal Incremental Value of 18F-FDG-PET and Cerebrospinal Fluid Biomarkers in Mild Cognitive Impairment Patients Suspected for Alzheimer’s Disease and Inconclusive First Biomarker

  2019cites this paper
• ATN status in amnestic and non-amnestic Alzheimer’s disease and frontotemporal lobar degeneration

  2019cites this paper
• Current state of Alzheimer’s fluid biomarkers

  2018cites this paper
• Automation vs. Experience: Measuring Alzheimer’s Beta-Amyloid 1–42 Peptide in the CSF

  2018cites this paper
• Upward drift in cerebrospinal fluid amyloid β 42 assay values for more than 10 years

  2018cites this paper
• Interlaboratory validation of cerebrospinal fluid α-synuclein quantification in the diagnosis of sporadic Creutzfeldt-Jakob disease

  2018cites this paper
• The technical reliability and biotemporal stability of cerebrospinal fluid biomarkers for profiling multiple pathophysiologies in Alzheimer’s disease

  2018cites this paper
• Proteomic Approaches for the Discovery of Biofluid Biomarkers of Neurodegenerative Dementias

  2018cites this paper
• Preanalytical approaches to improve recovery of amyloid-β peptides from CSF as measured by immunological or mass spectrometry-based assays

  2018cites this paper
• CSF biomarkers of Alzheimer’s disease concord with amyloid-β PETand predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts

  2018cites this paper
• Korean Brain Aging Study for the Early Diagnosis and Prediction of Alzheimer's Disease: Methodology and Baseline Sample Characteristics

  2017cites this paper
• Glypican-2 levels in cerebrospinal fluid predict the status of adult hippocampal neurogenesis

  2017cites this paper
• Alzheimer’s disease CSF biomarkers: clinical indications and rational use

  2017cites this paper
• Re-evaluation of soluble APP-α and APP-β in cerebrospinal fluid as potential biomarkers for early diagnosis of dementia disorders

  2017cites this paper
• Interprétation des biomarqueurs du liquide céphalorachidien dans la maladie d’Alzheimer et les dégénérescences lobaires fronto-temporales

  2017cites this paper
• Potential oxidative stress biomarkers of mild cognitive impairment due to Alzheimer disease.

  2017cites this paper
• Effect of long-term storage in biobanks on cerebrospinal fluid biomarker Aβ1-42, T-tau, and P-tau values

  2017cites this paper
• Cerebrospinal Fluid Aβ42/Aβ40 as a Means to Limiting Tube- and Storage-Dependent Pre-Analytical Variability in Clinical Setting

  2017cites this paper
• Imaging and fluid biomarkers in frontotemporal dementia

  2017cites this paper
• Accelerating drug development for Alzheimer's disease through the use of data standards

  2017cites this paper
• The Unbiased Search of Biomarkers in Neurodegenerative Diseases.

  2016cites this paper
• Novel Applications of Super-Resolution Microscopy in Molecular Biology and Medical Diagnostics

  2016cites this paper
• Performance Evaluation of an Automated ELISA System for Alzheimer’s Disease Detection in Clinical Routine

  2016cites this paper
• A Customized Quantitative PCR MicroRNA Panel Provides a Technically Robust Context for Studying Neurodegenerative Disease Biomarkers and Indicates a High Correlation Between Cerebrospinal Fluid and Choroid Plexus MicroRNA Expression

  2016cites this paper
• Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team

  2016cites this paper
• Validation of microRNAs in Cerebrospinal Fluid as Biomarkers for Different Forms of Dementia in a Multicenter Study

  2016cites this paper
• Combining Cerebrospinal Fluid Biomarkers and Neuropsychological Assessment: A Simple and Cost-Effective Algorithm to Predict the Progression from Mild Cognitive Impairment to Alzheimer’s Disease Dementia

  2016cites this paper
• No diurnal variation of classical and candidate biomarkers of Alzheimer’s disease in CSF

  2016cites this paper
• Cerebrospinal Fluid Aβ40 Improves the Interpretation of Aβ42 Concentration for Diagnosing Alzheimer’s Disease

  2015cites this paper
• MicroRNA (miRNA) Signaling in the Human CNS in Sporadic Alzheimer’s Disease (AD)-Novel and Unique Pathological Features

  2015cites this paper
• Comparative Study on Total Lipid Quantification and Oxidative Rancidity Determination in Freshwater Fish Species with Different Fat Levels

  2015cites this paper